SLG
KALV

Stanley-Laman Group’s KalVista Pharmaceuticals KALV Stock Holding History

Stanley-Laman Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-67,082
Closed -$545K – 231
2018
Q2 		$545K Buy
67,082
+21,861
+48% +$193K 0.12% 210
2018
Q1 		$429K Buy
+45,221
New +$473K 0.1% 226

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Stanley-Laman Group's KALV Position: Q3 2018 in Review

Stanley-Laman Group sold out of KalVista Pharmaceuticals (KALV) in Q3 2018, closing a stake of 67,082 shares — an estimated $545K sold.

Stanley-Laman Group first reported a position in KALV in Q1 2018 and held it in 2 quarters. The position peaked at $545K in Q2 2018. 48 funds tracked by Wall St. Rank hold KALV as of Q3 2018.

  • Stanley-Laman Group reported no remaining KalVista Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 67,082 KalVista Pharmaceuticals shares in Q3 2018, an estimated $545K.
  • Stanley-Laman Group first reported a position in KalVista Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Stanley-Laman Group's KalVista Pharmaceuticals position peaked at $545K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2018.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.